These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 21415001

  • 1. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N, Usui N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Takahara S, Ogasawara Y, Yamaguchi Y, Saito T, Yokoyama H, Aiba K.
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [Abstract] [Full Text] [Related]

  • 2. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
    Kurahashi S, Iwasaki T, Suzuki H, Sawamoto A, Sugimoto T, Narimatsu H, Adachi T, Hayakawa F, Sugiura I.
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1617-21. PubMed ID: 17940376
    [Abstract] [Full Text] [Related]

  • 4. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 7. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
    Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM.
    Natl Med J India; 2005 Nov; 18(1):12-5. PubMed ID: 15835484
    [Abstract] [Full Text] [Related]

  • 8. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 9. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():26-32. PubMed ID: 8692115
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A, Buffels R, Anagnostopoulos A, Gacos E, Vadikolia C, Haloudis P, Kaloyannidis P.
    Br J Haematol; 2002 Feb 12; 116(2):308-15. PubMed ID: 11841431
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [Abstract] [Full Text] [Related]

  • 14. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, Schacter BA.
    Cancer; 1998 Oct 01; 83(7):1344-54. PubMed ID: 9762935
    [Abstract] [Full Text] [Related]

  • 15. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U.
    Klin Padiatr; 2002 Oct 01; 214(4):188-94. PubMed ID: 12165900
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U.
    Klin Padiatr; 1992 Oct 01; 204(4):253-7. PubMed ID: 1518261
    [Abstract] [Full Text] [Related]

  • 17. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J.
    Cancer; 2005 May 15; 103(10):2082-90. PubMed ID: 15830348
    [Abstract] [Full Text] [Related]

  • 18. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct 15; 103(1):100-9. PubMed ID: 9792296
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC.
    J Clin Oncol; 2005 May 20; 23(15):3404-11. PubMed ID: 15824414
    [Abstract] [Full Text] [Related]

  • 20. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
    van Geel BM, Huijgens PC, Ossenkoppele GJ, Wijermans PW, Langenhuijsen MM.
    Neth J Med; 1989 Oct 20; 35(3-4):128-36. PubMed ID: 2601790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.